These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17044787)

  • 1. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
    Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
    Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma.
    Singh G; Parker S; Hobart P
    Vaccine; 2002 Jan; 20(9-10):1400-11. PubMed ID: 11818159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
    Hurvitz SA; Timmerman JM
    Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
    Patel KG; Ng PP; Levy S; Levy R; Swartz JR
    Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
    Leitch HA; Connors JM
    Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
    Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
    Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I; Qin H; Kwak LW
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
    Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M
    Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.
    Ruffini PA; Di Nicola M; Carlo-Stella C; Siena S; Gianni AM
    Curr Gene Ther; 2005 Oct; 5(5):511-21. PubMed ID: 16250891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
    Reinis M
    Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
    Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM
    Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
    Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.